TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10904459
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 5 mg/d
Study: 3521187
Drug: Single-drug chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug chemotherapy
Study: 22829267
Drug: MSC (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC (4 × 10(7) /injection) via intra-arterial and intravenous routes
Study: 18206738
Drug: No ICD
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ICD therapy (control group)
Study: 15999885
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (15 mL of 2% lidocaine administered intrarectally ten minutes before biopsy)
Study: 15999885
Drug: Lidocaine periprostatic
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine periprostatic infiltration (10 mL of 1% lidocaine given under ultrasound guidance in two periprostatic injections of 5 mL, four minutes before biopsy)
Study: 12450598
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (half-dose reteplase and full-dose abciximab)
Study: 12450598
Drug: Reteplase (standard-dose)
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reteplase (standard-dose)
Study: 7574130
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine and nebulized metaproterenol
Study: 2183055
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of continuous intravenous heparin with warfarin sodium begun on the first day
Study: 2183055
Drug: 10-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day course of intravenous heparin with warfarin sodium begun on the fifth day
Study: 2183055
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of continuous intravenous heparin
Study: 2183055
Drug: 10-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day course of intravenous heparin
Study: 6104634
Drug: GYKI-41099 2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GYKI-41099 2.5, 5 and 10 mg
Study: 6104634
Drug: Propranolol 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 10, 20 and 40 mg
Study: 6104634
Drug: GYKI-41099 5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: GYKI-41099 5-15 mg daily for 2 months
Study: 19169239
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 0.04 ml/1 mg
Study: 19169239
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy plus intravitreal triamcinolone (PDT+IVTA) 0.1 ml/4 mg
Study: 11345366
Drug: Bradykinin (BK)
Normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin (BK) administered at graded doses (0.2, 0.6, 2.0 microg/min) in ACE inhibitor group
Study: 11345366
Drug: Bradykinin (BK)
Normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin (BK) administered at graded doses (0.2, 0.6, 2.0 microg/min) in non-ACE inhibitor group
Study: 11345366
Drug: Papaverine (PA)
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine (PA) (12 mg)
Study: 8989000
Drug: Small-dose hypobaric
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose hypobaric solution of 1% lidocaine 25 mg with fentanyl 25 micrograms
Study: 8989000
Drug: Conventional-dose hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose hyperbaric solution of 5% lidocaine 75 mg
Study: 3315687
Drug: Theophylline preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline preparation (18 mg/kg per day at 2000 hours)
Study: 31197364
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish containing 1.5% ammonium fluoride applied every sixth week during orthodontic treatment.
Study: 31197364
Drug: Placebo varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo varnish without fluoride applied every sixth week during orthodontic treatment.
Study: 24166941
Drug: Non‐specific neurocognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐specific neurocognitive therapy (NNT)
Study: 19827964
Drug: Topical morphine
Normalized name: morphine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical morphine solution (2 per thousand)
Study: 17440161
Drug: PELFw regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PELFw regimen (8 weekly administrations of cisplatin 40 mg/m2, LV 250 mg/m2, epidoxorubicin 35 mg/m2, 5-FU 500 mg/m2, glutathione 1.5 g/m2 with filgrastim)
Study: 17440161
Drug: 5-FU/LV regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/LV regimen (6 monthly administrations of a 5-day course of 5-FU 375 mg/m2 daily and LV 20 mg/m2 daily)
Study: 12123399
Drug: 1000 mg/d
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/d ER niacin
Study: 12123399
Drug: 1500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/d ER niacin
Study: 10354968
Drug: Indinavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (800 mg every 8 hours from days 2 to 7)
Study: 9420871
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of micronized estradiol and progesterone (n = 7)
Study: 7316248
Drug: Rush Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rush Immunotherapy (IT) with four Ag dilutions: 10, 100, 1000, and 5000 pnu/ml, maintenance dose of 0.5 ml of the 5000 pnu/ml solution achieved in 7 to 18 weeks (mean 12 weeks).
Study: 30993855
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 units/mL (Gla-300)
Study: 17317857
Drug: Dasatinib (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (140 mg)
Study: 15345173
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (He-Ne laser applied to three trigger points in the upper trapezius muscles with 632.8 nm)
Study: 31186177
Drug: Automated Bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated Bone Scan Index (aBSI) increase during treatment
Study: 27564283
Drug: Doxazosin Oral
Normalized name: doxazosin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin Oral Intake Therapy (4 mg once daily for 4 weeks)
Study: 27564283
Drug: Doxazosin Oral
Normalized name: doxazosin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin Oral Intake Therapy
Study: 24169147
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 10 mg PO twice daily for six weeks
Study: 20407232
Drug: Late GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late GH therapy (0.46 mg/kg/week)
Study: 20407232
Drug: Early GH
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early GH therapy (0.46 mg/kg/week)
Study: 20407232
Drug: No GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GH therapy (Control)
Study: 9183129
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) titrated to a target dose of 0.7 mg/kg twice a day
Study: 3895761
Drug: Bepridil 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil 600 mg/day
Study: 30679315
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily (Arm A)
Study: 30679315
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily and panitumumab 4 mg/kg on days 1 and 15 of a 28-day cycle (Arm B)
Study: 21470787
Drug: High-dose external-beam
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose external-beam radiation therapy (EBRT) (79.2 Gray equivalent using photons and protons)
Study: 19865063
Drug: Alprazolam 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1.5 mg daily
Study: 11548897
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg Ginkgo biloba extract EGb 761 twice daily
Study: 11548897
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg Ginkgo biloba extract EGb 761 twice daily
Study: 7936250
Drug: 1H‐MRSI in
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1H‐MRSI in sequential studies
Study: 3124453
Drug: Thymopentin treatment
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin treatment (50 mg s.c. 3 times/week for 3 weeks and repeated after 3 months at 50 mg s.c. once a week for 3 months)
Study: 28554739
Drug: Descriptive norms
Normalized name: K Norm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Descriptive norms questions (e.g., 'What do you do with bikes?')
Study: 28554739
Drug: Preference questions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference questions (e.g., 'What do you like to do with bikes?')
Study: 28554739
Drug: Prescriptive norms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptive norms questions (e.g., 'What should you do with books?')
Study: 28554739
Drug: Preference questions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference questions (e.g., 'What do you like about books?')
Study: 27889725
Drug: 25 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL/kg IV normal saline over 6-8 hours
Study: 23510951
Drug: Ginger (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (1g capsules, two doses: one before induction and one 2h after surgery)
Study: 7767852
Drug: Ceftriaxone 1.5g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1.5g once daily
Study: 7767852
Drug: Cefotaxime 6g
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime 6g divided into four daily doses
Study: 2150591
Drug: CGS 16949A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16949A 0.9 mg
Study: 2150591
Drug: CGS 16949A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16949A 0.6 mg
Study: 25574686
Drug: GS-5806 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-5806 (oral RSV fusion inhibitor)
Study: 15472665
Drug: 1-visit root
Normalized name: Mugwort root
DrugBank: Artemisia vulgaris root (DB14170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-visit root canal treatment using AH 26 sealer and laterally compacted gutta-percha
Study: 15472665
Drug: 2-visit root
Normalized name: Mugwort root
DrugBank: Artemisia vulgaris root (DB14170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-visit root canal treatment with calcium hydroxide-chlorhexidine medication and temporary filling
Study: 8980871
Drug: light or
Normalized name: lake blend light orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: light or medication
Study: 3138303
Drug: Enprostil (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil (35 micrograms twice daily)
Study: 19291121
Drug: Solvent-free (SF)
Normalized name: solvent yellow 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solvent-free (SF) formulation
Study: 19291121
Drug: Solvent-containing (SC)
Normalized name: solvent yellow 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solvent-containing (SC) formulation
Study: 16790651
Drug: HIGH-group: 9.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH-group: 9.5 mg hyperbaric bupivacaine + 2.5 microg sufentanil
Study: 16790651
Drug: LOW-group: 6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW-group: 6.5 mg hyperbaric bupivacaine + 2.5 microg sufentanil
Study: 11105535
Drug: Conventional amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional amphotericin B 1 mg kg‐1 per day
Study: 11105535
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 1 mg kg‐1 per day
Study: 11105535
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 3 mg kg‐1 per day
Study: 11105535
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 1 mg kg‐1
Study: 11105535
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 3 mg kg‐1
Study: 3885425
Drug: Metronidazole tablets
Normalized name: Metronidazole Tablets
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole tablets (2 g single dose)
Study: 3885425
Drug: Benzoyl metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl metronidazole suspension (2 g single dose)
Study: 3885425
Drug: Tinidazole tablets
Normalized name: Tinidazole Tablets
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole tablets (2 g single dose)
Study: 3611299
Drug: Oral influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral influenza immunization in elderly volunteers
Study: 3611299
Drug: Oral influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral influenza immunization in young mice
Study: 3611299
Drug: Oral influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral influenza immunization in older mice
Study: 3611299
Drug: Oral influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral influenza immunization
Study: 3611299
Drug: Parenteral influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral influenza immunization
Study: 3611299
Drug: Secretory IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secretory IgA (SIgA) antibody response
Study: 3611299
Drug: Salivary antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary antibody response in elderly
Study: 18444059
Drug: Evidence-based psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based psychosocial treatments (EBTs)
Study: 16434737
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish twice/year
Study: 10882226
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (fluticasone propionate, FP, 250 microg twice daily)
Study: 10882226
Drug: Short-acting beta-agonist
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta-agonist (salbutamol, Sb, 400 microg twice daily)
Study: 8267238
Drug: Conventional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin lock
Study: 3884131
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) + semustine (MeCCNU) chemotherapy
Study: 28759735
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of 2% fat milk
Study: 28759735
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of soy beverage
Study: 28759735
Drug: 175 g
Normalized name: ALCOHOL 14.175 g in 10 / BENZALKONIUM CHLORIDE 0.042 g in 10 / DIDECYLDIMONIUM CHLORIDE 0.0567 g in 10 TOPICAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 g of 2% Greek yogurt
Study: 28759735
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of Cheddar cheese
Study: 19142758
Drug: Olmesartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (20 mg/day) administered at bedtime
Study: 19142758
Drug: Olmesartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (20 mg/day) administered upon awakening
Study: 17209146
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment in MDD-HF subjects
Study: 15025735
Drug: Fluticasone proprionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone proprionate (FP) 2000 micro g daily for 2 weeks
Study: 11862344
Drug: buprenorphine/naloxone (4/1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine/naloxone (4/1, 8/2, 16/4, 32/8 mg)
Study: 11862344
Drug: buprenorphine (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine (32 mg)
Study: 9814400
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (50 mg/kg/day divided tid)
Study: 9814400
Drug: Intramuscular penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular penicillin (50,000 units/kg)
Study: 2796618
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 0.5% Bupivacaine
Study: 2796618
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 0.5% Bupivacaine with 1 mL 10% G/W
Study: 2796618
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 0.5% Bupivacaine with 1 mL 10% G/W
Study: 2796618
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 0.5% Bupivacaine in 8% glucose
Study: 2796618
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of hyperbaric Bupivacaine
Study: 648737
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride (Slow‐K 600 mg three times daily)
Study: 648737
Drug: Spironolactone (Aldactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (Aldactone A 25 mg four times daily)
Study: 31293259
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (initiated at 8 hours post-operation)
Study: 31293259
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral feeding (initiated at 48 hours post-operation)
Study: 31293259
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral feeding
Study: 23416857
Drug: Methamphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (20 mg, oral) in paired conditions with contextual cues
Study: 23416857
Drug: Methamphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (20 mg, oral) in unpaired conditions
Study: 21203888
Drug: Treadmill exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill exercise at 65% of peak VO2 for 1 hour during MF and ML phases
Study: 19671089
Drug: Tramadol Contramid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol Contramid OAD 100 mg
Study: 17460496
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk (CM) with fish oil (FO) supplement
Study: 17460496
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula (IF) with fish oil (FO) supplement
Study: 11783823
Drug: Acupuncture, transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, transcutaneous electrical nerve stimulation, acupuncture‐like transcutaneous nerve stimulation, laser therapy, neuroreflexotherapy
Study: 9493258
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A treatment (one capsule)
Study: 9493258
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A treatment (two doses)
Study: 9493258
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A treatment (no pills taken)
Study: 18719064
Drug: Linezolid (LZD),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (LZD), 600 mg
Study: 18719064
Drug: Vancomycin (VAN),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (VAN), 1 g every 12 h
Study: 10704632
Drug: Atorvastatin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (initial dose 10 mg, max 80 mg)
Study: 10704632
Drug: Simvastatin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (initial dose 10 mg, max 40 mg, supplemented with 4 g cholestyramine if necessary)
Study: 10704632
Drug: Atorvastatin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (for baseline cholesterol 5.6-6.5 mmol/l)
Study: 10704632
Drug: Simvastatin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (for baseline cholesterol 5.6-6.5 mmol/l)
Study: 10704632
Drug: Atorvastatin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (for baseline cholesterol 7.6-8.5 mmol/l)
Study: 10704632
Drug: Simvastatin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (for baseline cholesterol 7.6-8.5 mmol/l)
Study: 9346224
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2) with carboplatin (AUC 7)